Search Results

Anavex Life Sciences Corp. announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held June 27, 2024.

Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York City.

Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended March 31, 2024, on Thursday, May 9, 2024.

Anavex Life Sciences Corp. today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference.

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system diseases, reported financial results for its fiscal quarter ended March 31, 2024.

Anavex Life Sciences Corp today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system diseases, announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference.

Anavex Life Sciences Corp. today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024.

Anavex Life Sciences Corp. today announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX®3-71 first-in-human study which achieved its safety objectives.